BioSpace News Archive

Agios Pharmaceuticals, Inc. presented detailed results from the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia in a plenary session at the European Hematology Association 2024 Hybrid Congress, which is being held June 13-16, 2024, in Madrid, Spain.

CARsgen Therapeutics Holdings Limited announces that the initial results from the ongoing first-in-human study of CT071 have been presented at the 29th Annual Congress of the European Hematology Association.

Genentech, a member of the Roche Group, announced statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi® in combination with gemcitabine and oxaliplatin versus Rituxan® in combination with GemOx for people with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy.

Sparrow Pharmaceuticals presented data from an ongoing Phase 2 clinical trial of HSD-1 inhibitor clofutriben and prednisolone in patients with polymyalgia rheumatica at the 2024 Annual European Alliance for Associations for Rheumatology that suggest HSD-1 inhibition can allow for effective treatment with glucocorticoid medicines with fewer side effects.

Johnson & Johnson announces patients treated with nipocalimab demonstrated statistically significant and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline in the Phase 2 DAHLIAS dose-ranging study of nipocalimab in adult patients living with Sjögren’s disease.

IASO biotechnology presented clinical data on the use of Equecabtagene Autoleucel, the world’s first approved fully human CAR-T product, for the treatment of transplant-ineligible patients with high-risk newly diagnosed multiple myeloma in an oral presentation at the 2024 European Hematology Association Annual Congress.